ReviewEye & contact lens2014
The core mechanism of dry eye disease is inflammation.
Review in Eye & contact lens, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 133 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
133 citing papers in PubMed, 6 syntheses or guidelines pooled it, 247 citations in OpenAlex.
- The Efficacy of Oral Vitamin Supplementation in Dry Eye Disease: A Systematic Review.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026Pooled it
- The effects of different forms of omega-3 polyunsaturated fatty acids on dry eye disease resulting from various etiologies: a meta-analysis and systematic review.BMC ophthalmology · 2026Pooled it
- Global research hotspots and trends in anti-inflammatory studies in dry eye: a bibliometric analysis (2004-2024).Frontiers in medicine · 2024Pooled it
- Association between asthma and dry eye disease: a meta-analysis based on observational studies.BMJ open · 2021Pooled it
- Cluster Analysis of Dry Eye Disease Models Based on Immune Cell Parameters - New Insight Into Therapeutic Perspective.Frontiers in immunology · 2020Pooled it
- Corneal lymphangiogenesis as a potential target in dry eye disease - a systematic review.Survey of ophthalmologyPooled it
- Treatment of Meibomian Gland Dysfunction by Classical Eyelid Hygiene Measures With and Without Additional Lipid Substitution for Tear Film Stabilization.Eye & contact lens · 2025Trial
- Longitudinal Analysis of Tear Cytokine Ratios in Association with Dry Eye Signs and Symptoms in the Dry Eye Assessment and Management (DREAM) Study.Current eye research · 2025Trial
- The Dry Eye Assessment and Management (DREAM) extension study - A randomized clinical trial of withdrawal of supplementation with omega-3 fatty acid in patients with dry eye disease.The ocular surface · 2020Trial
- n-3 Fatty Acid Supplementation for the Treatment of Dry Eye Disease.The New England journal of medicine · 2018Trial
- A novel TRPM8 agonist relieves dry eye discomfort.BMC ophthalmology · 2017Trial
- Efficacy of a fixed combination of 0.09 % xanthan gum/0.1 % chondroitin sulfate preservative free vs polyethylene glycol/propylene glycol in subjects with dry eye disease: a multicenter randomized controlled trial.BMC ophthalmology · 2016Trial
- Update on the Physiopathology of Keratoconus.Medical sciences (Basel, Switzerland) · 2026Review
- THBS1 inhibition alleviates inflammatory response by inhibiting TGF-β and NLRP3 inflammasome in experimental murine dry eye.Medical molecular morphology · 2026Article
- Integrative analysis of the meibum microbiome in dry eye disease: from dysbiosis and diagnostic biomarkers to immunomodulation by Bradyrhizobium-derived outer membrane vesicles.Journal of translational medicine · 2026Article
- IL-2: a promising topical treatment for Sjögren's disease-related dry eye disease.Arthritis research & therapy · 2026Article
- Trehalose as an anti-inflammatory agent: insights into molecular mechanisms and therapeutic applications.Inflammopharmacology · 2026Review
- Development of Autologous Serum Ocular Insert for Chronic Dry Eye Disease.Pharmaceutics · 2026Article
- Comorbidity of anxiety and dry eye disease: shared biomarkers and immune responses.Frontiers in immunology · 2026Article
- Associations of tear mediators with ocular surface symptoms, signs, and corneal nerve morphology in dry eye disease: a cross-sectional study.Frontiers in medicine · 2026Article
73 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
purposeThe purpose of this article is to review the evidence for the hypothesis that the core mechanism of dry eye disease (DED) is inflammation, including evidence from recent basic, clinical, and translational research involving human patients, animal models, and cell cultures.
methodsUsing the key words "dry eye + inflammation," the authors conducted a comprehensive search of the PubMed and Web of Science databases for scientific articles published in English between January 1, 1900 and August 30, 2013 on the role of inflammation in DED in cell cultures, animal models, and humans. The resulting articles were then categorized and reviewed.
resultsThe literature search revealed a total of 458 publications, almost all published after 1992. The percentages of original studies and review articles are 77.29% (354) and 22.71% (104), respectively. Among the original studies, the number of reports on human DED is 200 (43.7%), on animal models is 115 (25.1%), and cell cultures is 39 (8.5%). A yearly distributing plot revealed that 76% were published from 2003 to 2011, 53% from 2008 to 2012, and 11% during the first 9 months of 2013. This distribution signifies a rapidly growing awareness of the importance of inflammation in DED pathogenesis.
conclusionsInflammation plays a key role in the pathogenesis of DED as evidenced by research using tissue culture, animal models, and subjects with DED. Developing biomarkers for inflammation of the ocular surface will provide improved understanding of the mechanisms leading to DED, classification of the severity of DED, and objective metrics for outcome measures of treatment. The chronicity of the disease suggests that dysregulation of immune mechanisms leads to a cycle of continued inflammation, accompanied by alterations in both innate and adaptive immune responses. Given the underlying mechanism for DED, developing effective and safe anti-inflammatory treatments is likely to be beneficial for patients with DED.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.